Tumor Genomic Profiling Of Nsclc From The Phase Iii Trial Of First-Line S-1/Cbdca Versus Paclitaxel/Cbdca (Wjog6611ltr)

Hiroyasu Kaneda,Isamu Okamoto,Kazuko Sakai,Satoshi Morita,Koichi Takayama,Keisuke Tomii,Tadashi Maeda,Kazuhiko Nakagawa,Yoichi Nakanishi,Kazuto Nishio

ANNALS OF ONCOLOGY（2014）

引用 0|浏览0

暂无评分

摘要

Background: Over the last decade, substantial advances have been made in developing genotype-based target therapies for advanced NSCLC. There is an increasing need to develop high-throughput genotyping tests to evaluate larger number genetic abnormalities.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要